Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED

DOI: 10.1016/j.bmcl.2005.02.083
Bioorganic and Medicinal Chemistry Letters, 2005, 15, 2365-9

#	Paper	IF	Citations
23	Optimization of Purine Based PDE1/PDE5 Inhibitors to a Potent and Selective PDE5 Inhibitor for the Treatment of Male ED.. *ChemInform*, **2005**, 36, no		
22	Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2005**, 15, 3900-7	2.9	39
21	The purines: potent and versatile small molecule inhibitors and modulators of key biological targets. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3987-4006	3.4	247
20	Phosphodiesterase 5 inhibitors--drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. *Current Pharmaceutical Design*, **2006**, 12, 3459-65	3.3	50
19	Phosphodiesterases. **2007**, 919-957		4
18	Bioactivities of a series of phosphodiesterase type 5 (PDE-5) inhibitors as modelled by MIA-QSAR. *European Journal of Medicinal Chemistry*, **2008**, 43, 1632-8	6.8	15
17	In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 7599-606	3.4	20
16	Recent advances in the synthesis of purine derivatives and their precursors. *Tetrahedron*, **2008**, 64, 8585-8603	2.4	91
15	Three Heterocyclic Rings Fused (5-6-5). **2008**, 711-771		
14	Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. *Circulation: Heart Failure*, **2008**, 1, 272-80	7.6	43
13	N-Alkylated Guanine Derivatives. *Current Organic Chemistry*, **2009**, 13, 1085-1135	1.7	10
12	MIA-QSAR, PCA-ranking and least-squares support-vector machines in the accurate prediction of the activities of phosphodiesterase type 5 (PDE-5) inhibitors. *Molecular Simulation*, **2010**, 36, 871-877	2	3
11	PDE5 inhibitors and their applications. *Current Medicinal Chemistry*, **2010**, 17, 2564-87	4.3	21
10	The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences. *European Heart Journal*, **2010**, 31, 1188-96	9.5	70
9	Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. *Handbook of Experimental Pharmacology*, **2011**, 93-133	3.2	45
8	Methylxanthines. *Handbook of Experimental Pharmacology*, **2011**,	3.2	18
7	Effect of novel synthetic evodiamine analogue on sexual behavior in male rats. *Journal of Chemical Biology*, **2012**, 5, 35-42		10

6	Methods for the synthesis of xanthine-derived polycyclic fused systems. *Heterocyclic Communications*, **2013**, 19,	1.7	5
5	Scaffold-hopping and hybridization based design and building block strategic synthesis of pyridine-annulated purines: discovery of novel apoptotic anticancer agents. *RSC Advances*, **2015**, 5, 26051-26060	3.7	6
4	Scaffold-hopping from xanthines to tricyclic guanines: A case study of dipeptidyl peptidase 4 (DPP4) inhibitors. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 5534-5545	3.4	9
3	Microwave-Assisted Suzuki–Miyaura and Sonogashira Coupling of 4-Chloro-2-(trifluoromethyl)pyrido[1,2-e]purine Derivatives. *European Journal of Organic Chemistry*, **2019**, 2019, 5756-5767	3.2	4
2	The Medicinal Chemistry of Caffeine. *Journal of Medicinal Chemistry*, **2021**, 64, 7156-7178	8.3	13
1	Synthesis of 1,2,4-Triazin-5-ones through [4+2] Cycloaddition of 1,2,4-Triaza-1,3-dienes with Diphenylketene. *Heterocycles*, **2009**, 79, 627	0.8	2